Form 4: Ionis Pharmaceuticals Director B. Lynne Parshall Receives 2025 Equity Compensation

Ionis Pharmaceuticals Director B. Lynne Parshall was granted 11,518 non-qualified stock options and 5,220 restricted stock units as part of her 2025 annual equity compensation, totaling no more than $450,000 in aggregate grant date fair value.

Summary

• B. Lynne Parshall, a Director at Ionis Pharmaceuticals Inc. (IONS), received an equity grant on July 1, 2025.
• The grant included 11,518 non-qualified stock options with an exercise price of $39.94 per share.
• Additionally, 5,220 Restricted Stock Units (RSUs) were granted, each representing a contingent right to receive one share of Ionis common stock or its equivalent cash value.
• These grants were made pursuant to the Company's Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan.
• The total annual equity compensation for non-employee Directors in 2025 is adjusted downward to total no more than $450,000, based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718.
• Both the stock options and Restricted Stock Units vest 100% on either the first anniversary of the grant date (July 1, 2026) or the next regularly scheduled annual meeting of stockholders, whichever occurs earlier.
• The stock options become exercisable upon vesting and expire on June 30, 2035.
• The Restricted Stock Units will be delivered to the reporting person on July 15th following their vesting date.

Sentiment

Score: 7

Explanation: The document reports a routine and expected compensation event for a director, which is a positive for aligning management interests with shareholders but does not indicate a significant positive or negative operational or financial event for the company itself.

Positives

• The equity grants align the interests of Director B. Lynne Parshall with those of the shareholders, as her compensation is tied to the company's stock performance.
• The compensation structure is part of a pre-defined Non-Employee Director Compensation Policy, indicating a structured approach to governance.

Future Outlook

The granted stock options and Restricted Stock Units are scheduled to vest 100% on the first anniversary of the grant date (July 1, 2026) or the next regularly scheduled annual meeting of stockholders, whichever is earlier. The RSUs will be delivered on July 15th following their vesting date, and options will be exercisable upon vesting until June 30, 2035.

Management Comments

• Grants were adjusted downward such that the non-employee Director's annual equity compensation in 2025 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718.

Industry Context

The granting of stock options and restricted stock units to non-employee directors is a standard practice across the biotechnology and pharmaceutical industries. This compensation structure is designed to align the interests of the board members with the long-term performance of the company and its shareholders, encouraging strategic oversight and commitment.

Comparison to Industry Standards

• Director compensation packages, including equity components like stock options and RSUs, are common across publicly traded companies, particularly in the biotech sector where long-term value creation is paramount.
• While specific compensation amounts vary by company size, market capitalization, and industry, a total annual equity compensation limit of $450,000 for a non-employee director at a company like Ionis Pharmaceuticals (IONS) is generally within the expected range for a well-established biopharmaceutical firm, comparable to practices at companies such as Biogen Inc. (BIIB) or Gilead Sciences, Inc. (GILD) for similar roles, though exact figures would require detailed peer analysis.

Corporate Governance

Related Party Transactions

• The grant of equity compensation to B. Lynne Parshall, a Director of Ionis Pharmaceuticals, constitutes a related party transaction, which is a standard and disclosed practice for compensating board members.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with shareholder value creation, as the value of the compensation is tied to the company's stock performance.
• Management: The compensation policy provides a clear framework for rewarding non-employee directors, contributing to stable governance.

Next Steps

• The stock options and Restricted Stock Units will vest on July 1, 2026, or the next annual meeting, whichever is earlier.
• The Restricted Stock Units will be delivered to the reporting person on July 15th following their vesting date.
• The stock options will become exercisable upon vesting and can be exercised until their expiration date of June 30, 2035.

Key Dates

Keywords

Ionis Pharmaceuticals, IONS, SEC Form 4, Director Compensation, Stock Options, Restricted Stock Units, Equity Grant, Insider Transaction, Corporate Governance, Biotechnology